Official event dates: January 11–15, 2021
Post-show access until March 31, 2021Biotech Showcase On Demandkeyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Biotech Showcase On Demand - PST/PDT (Pacific Daylight, GMT-7)
keyboard_arrow_leftSearch & Filter
search
Streams
Formats
Biotech Showcase On Demand - PST/PDT (Pacific Daylight, GMT-7)
search
Streams
Formats
Session content is available on-demand in partneringONE until March 31
Biotech Showcase On Demand 12:35am - 1:35am60 mins
Biotech Showcase
Media round-up live: Heard virtually around the social media square
- Kimberly Ha - CEO and Founder, KKH Advisors
- Alaric DeArment - Reporter, Scrip
- Moira Gunn - Host of Tech Nation and Professor, NPR, University of San Francisco
- Virginia Li - Associate Editor, BioCentury
- Sony Salzman - Coordinating Producer, Medical Unit, ABC
On Demand
Biotech Showcase
OPEN SESSION - Diversity: Investing in diversity
- Paul J. Hastings - President and CEO, Nkarta Therapeutics, Inc. (NASDAQ GS: NKTX)
- Lucy Abreu - Senior VP, Diversity, Equity and Inclusion Strategist and Employee Engagement Lead, Syneos Health Communications
- Julia Levy - Founder and Former CEO, QLT Inc.
- Anthony Sun - CEO, Zentalis Pharmaceuticals (NASDAQ: ZNTL)
- Meg Zweig - COO, Rock Health
On Demand
Biotech Showcase
Let’s Discuss Women’s Healthcare: An under-tapped investment opportunity
- Jennifer Friel Goldstein - Managing Partner, Life Science and Healthcare, SVB Capital
- Berthold Hinzen - VP and Head of Business Development and Licensing, Therapeutic Areas, Bayer AG
- Taja Lester - Managing Partner, Health Equity Capital
- Gail Maderis - President and CEO, Antiva Biosciences
- Debora Spar - Professor and Senior Associate Dean, Harvard Business School
On Demand
Biotech Showcase
Cardiovascular and nephrology: a renewed interest
- Bibhash Mukhopadhyay - Principal, New Enterprise Associates (NEA)
- Philippe Alen - Head of Cardiovascular Business Development Licensing & Alliance Management, Bayer SA-NV
- Grace Colon - CEO, InCarda Therapeutics Inc.
- Arthur Klausner - President and CEO, Goldilocks Therapeutics, Inc.
On Demand
Biotech Showcase
Cell and gene therapy
- Mani Foroohar - Managing Director and Senior Research Analyst, SVB Leerink
- Arjun Goyal - Co-Founder and Managing Director, Vida Ventures
- Rachel Haurwitz - President and CEO, Caribou Biosciences, Inc.
- Rachelle Jacques - CEO, Enzyvant
- Jak Knowles - CBO, Metagenomi
- Geoff MacKay - CEO, AVROBIO (NASDAQ: AVRO)
On Demand
Biotech Showcase
CNS: Following the innovation
- Marc Goodman - Managing Director, SVB Leerink Equity Research, Neuroscience
- Phyllis Barkman - Global Head, External Engagement, Alzheimer’s disease and Neurodegeneration, Eli Lilly & Company
- Kyle Gano - Chief Business Development and Strategy Officer, Neurocrine Biosciences (NASDAQ: NBIX)
- Abraham Heifets - Co-Founder and CEO, Atomwise
- Tracy Saxton - Managing Director, Dolby Family Ventures
On Demand
Biotech Showcase
Diagnostics: The coming of age of diagnostics
- Steve Dickman - CEO, CBT Advisors
- Rahul Dhanda - Co-Founder and CEO, Sherlock Biosciences
- Jeff Hawkins - CEO, Truvian Health
- Madeline Repollet - Head of Clinical Laboratories, ANGLE plc
- Ajit Singh - Partner, Artiman Ventures
On Demand
Biotech Showcase
Oncology: The in-rush of funds for IO and non-IO
- Jeffrey Bockman - Executive VP and Oncology Practice Head, Cello Health BioConsulting
- Asthika Goonewardene - Managing Director and Senior Analyst, Truist Securities
- Taylor Guo - Co-Founder and CSO, I-Mab Biopharma
- Matthias Müllenbeck - Executive Director & Head Global Licensing and Business Development Enabling Technologies Biopharma, Global Business Development and Alliance Management, Merck KGaA, Darmstadt, Germany
- Christopher Mortko - Associate VP, Merck & Co Inc.
- Laura Stoppel - Principal, RA Capital Management
On Demand
Biotech Showcase
In conversation with the COVID-19 leaders: A sense of urgency and collaboration
- Paul Colvin - President, Clinical Solutions, Syneos Health
- Kumar Srinivasan - VP and Global Head of Business Development and Licensing, BioPharmaceuticals R&D, AstraZeneca Pharmaceuticals
On Demand
Biotech Showcase - INSIGHTS
Clinical Studies in 2021: The changing dynamics and challenges of getting studies done rapidly
- Ben Bonifant - Partner, Triangle Insights Group, LLC
- Andrew Schachter - Founder and CEO, Axiom Real-Time Metrics
On Demand
Biotech Showcase - INSIGHTS
Patients first: A path to better outcomes for everyone
- Ted Haack - VP, Lattice Point Consulting
- Peyton Howell - Executive VP, CCO and CSO, Parexel
On Demand
Biotech Showcase
Part 1 - The world according to COVID-19: From crisis to long-term impact
- Leah Rosenbaum - Assistant Editor, Healthcare & Science, Forbes
- Jeremy Levin - CEO, Ovid Therapeutics; Board of Directors Chair, Biotechnology Innovation Organization (BIO)
- Michelle McMurry-Heath - President and CEO, Biotechnology Innovation Organization (BIO)
On Demand
Biotech Showcase - INSIGHTS
The Anatomy of an Acquisition: Bayer and AskBio
- Stephanie Léouzon - Partner and Head, Torreya Europe
- Marianne De Backer - Executive VP, Head of Strategy, Business Development & Licensing and Executive Committee Member, Bayer AG, Pharmaceuticals
- Sheila A. Mikhail - Co-Founder and CEO, Asklepios BioPharmaceutical, Inc. (AskBio)
On Demand
Biotech Showcase - INSIGHTS
Hindsight is 2020: Lessons learned from DCTs and 2021 predictions
- Alison Holland - Head of Decentralized and Remote Trials, Medable
- Craig Lipset - Managing Partner, Clinical Innovation Partners LLC
On Demand
Biotech Showcase
Part 2 - The world according to COVID-19: Inside Operation Warp Speed
- Michelle McMurry-Heath - President and CEO, Biotechnology Innovation Organization (BIO)
- Jeremy Levin - CEO, Ovid Therapeutics; Board of Directors Chair, Biotechnology Innovation Organization (BIO)
- Moncef Slaoui - Scientific Head, Operation Warp Speed
On Demand
Biotech Showcase - INSIGHTS
Endless Frontier Labs – A model for success
- Linda Brown - Advisory Board Member, New Jersey Bioscience Center Incubator
- Deepak Hegde - Associate Professor of Management and Organizations and Director, Endless Frontier Labs, New York University, Stern School of Business
- Robert J. Schneider - Albert Sabin Professor of Molecular Pathogenesis, NYU School of Medicine, Alexandria Center for Life Sciences
On Demand
Biotech Showcase
In conversation with the COVID-19 leaders: In the balance — the humanitarian perspective - global policy
- Jeremy Abbate - Publisher, Scientific American
- Ruxandra Draghia-Akli - Global Head, Johnson & Johnson Global Public Health R&D
- Amy Finan - CEO, Sabin Vaccine Institute
- Richard Hatchett - CEO, CEPI
On Demand
Biotech Showcase
In conversation with the COVID-19 leaders: COVID-19 therapeutics: A review of the options
- Stephen G. Brozak - Managing Partner and President, WBB Securities LLC
- Prabhavathi Fernandes - Chair, National Biodefense Science Board
- Michael Kurilla - Director of Division of Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
On Demand
Biotech Showcase
Post-election policy and drug development: now what?
- Alice Valder Curran - Partner, Hogan Lovells
- Julie Gerberding - Executive VP and Chief Patient Officer, Merck & Co. Inc.
- Peter Kolchinsky - Founder and Managing Partner, RA Capital Management
- Greg Simon - Consultant, Simonovation LLC
On Demand
Biotech Showcase
In conversation with the COVID-19 leaders: Fulfilling the manufacturing promise for the global supply chain
- Melissa Fassbender - Former Journalist, Associate Director of External Communications, Polsky Center for Entrepreneurship & Innovation, University of Chicago
- Katherine Eban - Contributing Editor, Investigative Journalist, Author: Bottle of Lies: the Inside Story of the Generic Drug Boom, Vanity Fair
- Robin Robinson - CSO and Founding Director, RenovaCare, BARDA
On Demand
Biotech Showcase
In conversation with the COVID-19 leaders: The path forward
- Sara Jane Demy - CEO and Founder, Demy-Colton
- Rick Bright - Former Director, Biomedical Advanced Research and Development Authority (BARDA), Transition Team, COVID-19 Advisory Board
On Demand
Biotech Showcase
The pharma perspective: The unintended positive consequences of COVID-19
- Sam Fazeli - Director of EMEA Research and Senior Pharmaceutical Analyst, BI, Bloomberg L.P.
- Marianne De Backer - Executive VP, Head of Strategy, Business Development & Licensing and Executive Committee Member, Bayer AG, Pharmaceuticals
- Shaun Grady - Senior VP of Business Development Operations, AstraZeneca
- Leanne Larson - Senior VP, Real-World Evidence & Access, Parexel
- Philippe Lopes-Fernandes - Executive VP and CBO, Ipsen
- John McDonald - Corporate VP and Global Head Business Development, Novo Nordisk
On Demand
Biotech Showcase
The year of the IPO and the coming of age of the SPACs
- William Kolb - Partner, Foley Hoag
- Gabriel P. Cavazos - Managing Director, Investment Banking, SVB Leerink
- Paul J. Hastings - President and CEO, Nkarta Therapeutics, Inc. (NASDAQ GS: NKTX)
- Art Pappas - Managing Partner, Pappas Capital
- Scott Platshon - Principal, EcoR1 Capital
- Laura Shawver - CEO, Silverback Therapeutics (NASDAQ: SBTX)
On Demand
Biotech Showcase
In conversation with the COVID-19 leaders: The Novavax COVID-19 Journey
- Kimberly Ha - CEO and Founder, KKH Advisors
- John J. Trizzino - Executive VP, CCO and CBO, Novavax
On Demand
Biotech Showcase
In conversation with the COVID-19 leaders: The UK perspective
- Jaime E. Hernandez - Executive Medical Director, Infectious Disease and Vaccines, Syneos Health
- Steve Bates - CEO, BioIndustry Association
- Kate Bingham - Former Chair U.K. Vaccine Taskforce, Managing Partner, SV Health Managers LLP
On Demand
Biotech Showcase
Value creation and venture
- Jeff Cranmer - BioCentury Inc., BioCentury Inc.
- Eric Aguiar - Partner, Aisling Capital LLC
- Marian T. Nakada - VP Venture Investments, Johnson & Johnson Innovation, JJDC
- Rafaèle Tordjman - Founder and CEO, Jeito Capital
- Stella Xu - Managing Director, Quan Capital
On Demand
Biotech Showcase
The Investors' View: Where is the money going in 2021?
- Dennis J. Purcell - Founder and Senior Advisor, Aisling Capital
- Mara Goldstein - Managing Director, Mizuho Securities USA
- Nina Kjellson - General Partner, Canaan
- Camille Samuels - Partner, Venrock
On Demand
Biotech Showcase
Infectious Disease - COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace
- Yasmeen Rahimi - Senior Research Analyst, Piper Sandler
- Sean Marett - CBO and CCO, BioNtech (NASDAQ: BNTX)
- Joseph Payne - President and CEO, Arcturus Therapeutics, Inc.
- Scot Roberts - CSO, Altimmune (NASDAQ: ALT)
On Demand
Rare Beyond the Square
OPEN SESSION - From de-risking to value creation – The evolving role of patient communities in rare disease drug development and commercialization
- Sara Nayeem - Partner, NEA
- Dave Greenwald - VP, Deerfield Management
- Rich Horgan - Founder, Cure Rare Disease
- Vijay Sappani - Founder and CEO, Ela Capital, CDG Canada
- Walt Kowtoniuk - Partner, Third Rock
On Demand
Biotech Showcase
To spend or not to spend: Investing for commercial success as an emerging company
- Naveen Murthy - Senior Managing Director and Head of Product & Franchise Strategy, Commercial Advisory Group, Consulting, Syneos Health
- Sachin Purwar - Director of Commercial Advisory Group, Consulting, Syneos Health
- Michael Sarshad - Director of Commercial Advisory Group, Consulting, Syneos Health
- Ram Aiyar - CEO, Korro Bio
- Adele Gulfo - CBO and Commercial Development Officer, Sumitovant Biopharma
- Aziz Mottiwala - CCO, Tarsus Pharmaceuticals
- Vicki Vakiener - CCO, Epizyme
On Demand
Rare Beyond the Square
A film selection from The Disorder Channel: Unfixed - Covid: How We're Affected
On Demand
Biotech Showcase
Alliance for Regenerative Medicine’s annual cell & gene state of the industry briefing
- Janet Lambert - CEO, Alliance for Regenerative Medicine
On Demand
Rare Beyond the Square
Leveraging platform approaches to gene therapies to accelerate therapeutic development for monogenic diseases
- Allyson Berent - CSO and COO, Foundation for Angelman Syndrome Therapeutics, GeneTx Biotherapeutics
- P.J. Brooks - Program Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), NIH
- Nicole Guadelli - Director and Head of Gene Editing Technologies, Beam Therapeutics
- Nick Leschly - Chief Bluebird, bluebird bio
- Peter Marks - Director of Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
On Demand
Biotech Showcase
Looking Ahead – What to expect for the cell & gene therapy sector in 2021 and beyond
- Janet Lambert - CEO, Alliance for Regenerative Medicine
- Terry-Ann Burrell - CFO, Beam Therapeutics
- Marianne De Backer - Executive VP, Head of Strategy, Business Development & Licensing and Executive Committee Member, Bayer AG, Pharmaceuticals
- Sandy Macrae - President & CEO, Sangamo Therapeutics
- Ken Mills - President and CEO, REGENXBIO
- Adrian Rawcliffe - CEO, Adaptimmune
On Demand
Rare Beyond the Square
Advancing patient-centered value frameworks for novel therapeutics in rare disease
- Diane Berry - Senior VP, Global Health Policy, Government and Patient Affairs, Sarepta Therapeutics
- Donna Cryer - President and CEO, Global Liver Institute
- Jeremy Levin - CEO, Ovid Therapeutics; Board of Directors Chair, Biotechnology Innovation Organization (BIO)
Filter
Streams
Formats